Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo–PrPCbinding and downstream pathways
Citations Over Time
Abstract
Amyloid β oligomers (Aβo) are the main toxic species in Alzheimer's disease, which have been targeted for single drug treatment with very little success. In this work we report a new approach for identifying functional Aβo binding compounds. A tailored library of 971 fluorine containing compounds was selected by a computational method, developed to generate molecular diversity. These compounds were screened for Aβo binding by a combined 19F and STD NMR technique. Six hits were evaluated in three parallel biochemical and functional assays. Two compounds disrupted Aβo binding to its receptor PrPC in HEK293 cells. They reduced the pFyn levels triggered by Aβo treatment in neuroprogenitor cells derived from human induced pluripotent stem cells (hiPSC). Inhibitory effects on pTau production in cortical neurons derived from hiPSC were also observed. These drug-like compounds connect three of the pillars in Alzheimer's disease pathology, i.e. prion, Aβ and Tau, affecting three different pathways through specific binding to Aβo and are, indeed, promising candidates for further development.
Related Papers
- → Hierarchical virtual screening approaches in small molecule drug discovery(2014)154 cited
- → Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery(2017)85 cited
- → Multi-label classification using deep belief networks for virtual screening of multi-target drug(2016)4 cited
- Virtual screening and new drug discovery(2005)
- [Research progress of virtual screening aided drug discovery].(2009)